12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Krystexxa pegloticase regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Krystexxa pegloticase from Savient to treat severe chronic tophaceous gout in adult patients - its approved indication. NICE said the most plausible incremental cost-effectiveness ratio (ICER) for Krystexxa would be greater than £66,000...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >